RANTES and IL-6 cooperate in inducing a more aggressive phenotype in breast cancer cells
Authors:
- Marianna GalloMGMarianna Gallo
- Daniela FrezzettiDFDaniela Frezzetti
- Cristin RomaCRCristin Roma
- Nicoletta ChicchinelliNCNicoletta Chicchinelli
- Antonio BarbieriABAntonio Barbieri
- Giosuè ScognamiglioGSGiosuè Scognamiglio
- Gerardo BottiGBGerardo Botti
- Antonella De LucaAntonella De Luca
- Nicola NormannoNicola Normanno
Open Access
- 3 April 2018
- journal article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 9 (25) , 17543-17553
Abstract
RANTES and IL-6 cooperate in inducing a more aggressive phenotype in breast cancer cells RANTES and IL-6 cooperate in inducing a more aggressive phenotype in breast cancer cellsKeywords
This publication has 27 references indexed in Scilit:
- Expression and functional role of CRIPTO-1 in cutaneous melanomaBritish Journal of Cancer, 2011
- Zoledronic acid blocks the interaction between mesenchymal stem cells and breast cancer cells: implications for adjuvant therapy of breast cancerAnnals of Oncology, 2011
- CCL5 promotes proliferation of MCF-7 cells through mTOR-dependent mRNA translationBiochemical and Biophysical Research Communications, 2009
- Interleukin-6 induces an epithelial–mesenchymal transition phenotype in human breast cancer cellsOncogene, 2009
- The metastatic niche: adapting the foreign soilNature Reviews Cancer, 2009
- Metastasis: from dissemination to organ-specific colonizationNature Reviews Cancer, 2009
- Fibroblasts Isolated from Common Sites of Breast Cancer Metastasis Enhance Cancer Cell Growth Rates and Invasiveness in an Interleukin-6–Dependent MannerCancer Research, 2008
- The inflammatory chemokines CCL2 and CCL5 in breast cancerCancer Letters, 2008
- Interleukin‐6 is a potent growth factor for ER‐α‐positive human breast cancerThe FASEB Journal, 2007
- Inhibition of metastasis by inhibition of tumor-derived CCL5Breast Cancer Research and Treatment, 2005